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Purpose: The effect of travoprost 0.004% on 24-hour intraocular pressure (IOP) was examined 
in patients with normal tension glaucoma (NTG).
Subjects and methods: This study included 17 patients with newly diagnosed unilateral NTG. 
IOP was measured at three-hour intervals over 24 hours by Goldman applanation tonometer in 
patients taking topical travoprost 0.004% and was compared retrospectively with 24-hour IOP 
data in untreated eyes.
Results: IOP values were significantly reduced at individual time points after treatment 
(P , 0.01). Mean 24-hour IOP, maximum 24-hour IOP, minimum 24-hour IOP, and 24-hour IOP 
fluctuations at baseline (mean ± SD) were 12.9 ± 2.2 mmHg, 15.4 ± 2.7 mmHg, 10.5 ± 2.2 mmHg, 
and 4.9 ± 1.2 mmHg, respectively, and were significantly reduced to 10.3 ± 2.0 mmHg, 
12.4 ± 2.5 mmHg, 8.5 ± 1.9 mmHg (all P , 0.001), and 3.9 ± 1.5 mmHg (P , 0.05), respec-
tively, after treatment. The rate of IOP reduction greater than 20% was 58.8% (10 eyes) for 
maximum 24-hour IOP and 53.0% (nine eyes) for mean 24-hour IOP.
Conclusion: Travoprost reduced IOP throughout the 24-hour study period, with over half of 
the eyes examined showing IOP reduction exceeding 20%.
Keywords: 24-hour intraocular pressure, fluctuation, normal tension glaucoma, travoprost, 
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Introduction
Elevated intraocular pressure (IOP) is a primary risk factor for the development of 
glaucoma. However, some patients develop glaucomatous damage to the optic nerve 
in the absence of elevated IOP, known as normal tension glaucoma (NTG). The 
importance of lowering IOP to reduce the progression of glaucomatous damage was 
demonstrated by the Collaborative Normal Tension Glaucoma (CNTG) study group 
which showed that lowering IOP by 30% from baseline reduces the risk of progres-
sion of visual field loss in NTG patients. However, 12% of treated patients progressed 
during five years of follow-up versus 35% of an untreated group.1,2
The Early Manifest Glaucoma Trial (EMGT) indicated that IOP fluctuation is not a 
risk factor for the progression of glaucoma.3 However, some reports have shown that 
circadian IOP, diurnal IOP fluctuation, and maximum diurnal IOP are also important 
factors influencing the progression of glaucoma.4–6 IOP fluctuation remains a contro-
versial issue that has not yet been resolved. However, present management of NTG 
involves achieving the best possible reduction in IOP over a 24-hour period.
Once patients begin to use antiglaucoma eye drops, their IOP curve is altered, 
and estimation of maximum IOP becomes difficult. Wilensky et al7 conducted a Clinical Ophthalmology: 2010:4 submit your manuscript | www.dovepress.com
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study of 24-hour IOP measured with a home tonometer in 
patients with well-controlled IOP and found that a half of 
the maximum IOP measurements were obtained outside of 
clinic hours. This study shows the importance of measuring 
IOP throughout a 24-hour period.7,8
Prostaglandin analogs can strongly reduce IOP compared 
with beta-blockers or carbonic anhydrase inhibitors.9,10 
Latanoprost 0.005% and bimatoprost 0.03%, both prostaglan-
din analogs, are effective in reducing IOP in NTG patients.10–13 
Another prostaglandin analog, travoprost 0.004%, has been 
shown to be equivalent in the reduction of IOP in primary 
open angle glaucoma and ocular hypertension.9,14–16 However, 
only two reports have investigated the effect of travoprost on 
NTG.17,18 Suh et al17 reported the effect of travoprost on clinic 
IOP measurements in patients with NTG over a 12-month 
period, and Ang et al18 reported the effect of travoprost on 
daytime IOP in NTG patients. Neither group measured 
changes in IOP overnight in NTG patients. To the best of our 
knowledge, the present study is the first to evaluate the effect 
of travoprost 0.004% on 24-hour IOP in NTG patients.
Subjects and methods
The study group comprised 17 newly diagnosed patients 
with unilateral NTG treated with travoprost 0.004% in one 
eye for one to two months. The patients were admitted to 
Osaka City University Hospital between January 2008 and 
October 2008 to evaluate their 24-hour IOP whilst receiving 
topical travoprost 0.004%.
All patients agreed to undergo 24-hour IOP   measurements 
and signed informed consent forms in accordance with 
the   Declaration of Helsinki. A complete slit examination, 
gonioscopic evaluation, and dilated fundus examination were 
performed by glaucoma specialists in the clinic. Visual acu-
ity, visual field tests (Humphrey 30-2 or 24-2 SITA program, 
Humphrey Field Analyzer, Carl Zeiss Meditec, Dublin, CA), 
and measurement of central corneal thickness by specular 
microscope (SP-3000P, Topcon, Tokyo) were also conducted. 
A diagnosis of NTG was made if criteria were fulfilled for glau-
comatous optic disc change, the presence of visual field defects 
typical of glaucoma, and both clinic and untreated 24-hour 
IOP were ,21 mmHg. Patients with congenital, secondary, or 
narrow angle glaucoma, ocular inflammation, a severe corneal 
disorder, or a history of ocular surgery were excluded.
During hospitalization, IOP was measured in patients in 
the sitting position with a Goldmann applanation tonometer 
at three-hour intervals from midnight to 9:00 am by the same 
doctor. Patients self-administered travoprost 0.004% to the 
treated eye at night in their usual manner. For   nighttime 
  measurements, patients were gently awakened and walked 
10–20 meters to the tonometer. Immediately after IOP 
  measurement, patients returned to their beds. Mean 24-hour 
IOP was determined as the mean of the eight IOP measure-
ments recorded. Fluctuation in 24-hour IOP was calculated as 
the difference between maximum 24-hour IOP and minimum 
24-hour IOP. Clinic IOP was measured between 10:00 am and 
6:00 pm at approximately the same time for each patient.
We used Travatan ZTM ophthalmic solution 0.004% 
(Alcon Japan Limited, Tokyo), which is the prostaglandin 
analog product without benzalkonium chloride (BAK) and 
which has a similar IOP reduction efficacy and safety   profile 
as does travoprost with BAK.19 Each patient’s 24-hour IOP 
data following administration of travoprost were retro-
spectively compared with their 24-hour IOP data obtained 
in the same manner from the same untreated eye at one to 
two months prior to treatment.
statistical analysis
Values are shown as means ± standard deviation (SD). We 
used the paired t-test to analyze the differences between IOP 
at individual time points before and after treatment for both 
eyes, maximum 24-hour IOP, minimum 24-hour IOP, clinic 
IOP, and 24-hour IOP fluctuation before and after treat-
ment in the treated eye. Paired t-tests and post hoc testing 
(Bonferroni correction) were used to analyze differences 
between the different time points of each IOP curve (treated 
eye and fellow eye before and after treatment). A P value 
of ,0.05 was considered statistically significant.
Results
Patients
We included 17 newly diagnosed unilateral NTG patients in 
the present study (right eye, n = 6; left eye, n = 11). The patients 
comprised nine men and eight women with a mean age of 
63.1 ± 14.3 (range 31–81) years. Average central corneal 
thickness for both eyes was 515.8 ± 34.6 µM. Mean devia-
tion was −7.3 ± 3.3 dB (range −3.3–15.0) in the treated eyes. 
Data for 24-hour IOP in both eyes are shown in Table 1. At all 
individual time points, IOP was significantly decreased after 
travoprost treatment in the treated eye (P , 0.01, Figure 1). 
There were no significant reductions in IOP at each time point 
in untreated fellow eyes (P . 0.05, Figure 2).
Multiple comparisons between  
iOP curves
Before treatment, there was a significant difference in IOP 
curves between 9:00 am and 12 pm, 12 pm and 9:00 pm, Clinical Ophthalmology: 2010:4 submit your manuscript | www.dovepress.com
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Figure 1 IOP measurements from the travoprost-treated eye over 24 hours. There is a significant reduction in IOP at each time point (P , 0.01). The 24-hour iOP curve 
also shifted toward a lower iOP.
Abbreviation: iOP, intraocular pressure.
Table 1 Mean baseline and post-treatment iOP values
Treated eye Untreated fellow eye
Baseline Travoprost Before After
9:00 am 12.6 ± 2.5 10.4 ± 1.9 11.9 ± 2.2 12.4 ± 2.4
12:00 pm 14.5 ± 2.6 11.0 ± 2.3 13.5 ± 2.5 13.5 ± 2.9
3:00 pm 13.4 ± 2.7 10.4 ± 2.2 12.5 ± 2.6 12.5 ± 2.7
6:00 pm 13.7 ± 2.6 10.3 ± 2.0 12.7 ± 2.4 12.8 ± 2.4
9:00 pm 12.0 ± 2.4 9.4 ± 2.6 11.5 ± 2.0 11.4 ± 2.7
12:00 am 12.2 ± 3.2 10.41 ± 2.9 11.8 ± 2.3 11.9 ± 2.9
3:00 am 12.5 ± 3.4 10.3 ± 2.8 12.1 ± 2.6 11.3 ± 2.8
6:00 am 12.8 ± 2.2 10.5 ± 2.4 12.2 ± 2.6 11.5 ± 2.7
Values indicate mean mmhg ± sD.
Abbreviations: iOP, intraocular pressure; sD, standard deviation.
12:00 pm and 12:00 am, and 12:00 pm and 3:00 am in the 
treated eye, and between 12:00 pm and 9:00 pm and 12:00 pm 
and 12:00 am in the untreated eye. After treatment, there was 
no significant difference in IOP curves between these times in 
the treated eyes. However, there was a significant difference 
in IOP curves between 12:00 pm and 12:00 am, 12:00 pm and 
3:00 am, and 12:00 pm and 6:00 am in the untreated eye.
Clinic IOP was reduced by 24.3% (from 14.8 ± 2.7 mmHg 
to 11.2 ± 2.4 mmHg, P , 0.001). Mean 24-hour IOP was 
reduced by 20.2% (from 12.9 ± 2.2 mmHg to 10.3 ± 2.0 mmHg, 
P , 0.001). Maximum 24-hour IOP decreased 19.5% (from 
15.4 ± 2.7 mmHg to 12.4 ± 2.5 mmHg, P , 0.001), and 
minimum 24-hour IOP was reduced by 19.0% (from 10.5 ± 
2.2 mmHg to 8.5 ± 1.9 mmHg, P , 0.001).   Fluctuation in 
24-hour IOP was flattened by 20.4% (from 4.9 ± 1.2 mmHg 
to 3.9 ± 1.5 mmHg, P , 0.05, Table 2).
The percentage reduction of each parameter in the treated 
eye is shown in Table 3. The rate of .30% reduction in 
maximum 24-hour IOP was 23.5% and in mean 24-hour 
IOP was 11.8%. The rate of .20% reduction was 58.8% in 
maximum 24-hour IOP and 53.0% in mean 24-hour IOP. 
Categorization as a travoprost nonresponder (TNR), defined 
as a mean 24-hour IOP reduction ,10%, occurred in two 
eyes (11.8%). No serious treatment-related adverse events 
were observed in this study, and any adverse events that did 
occur were mild and controllable.
Discussion
The present study is the first to show the effect of travoprost 
on 24-hour IOP in NTG patients. In this study, the rate of IOP 
reduction was 20.2% for mean 24-hour IOP, 19.5% for maxi-
mum 24-hour IOP, and 20.4% for 24-hour IOP fluctuation. 
The results of this study indicate that travoprost can reduce 
IOP throughout a 24-hour period and flatten the IOP curve.
In the present study, travoprost reduced clinic IOP by 
24.3%. In previous studies, IOP reduction by latanoprost 
0.005% and bimatoprost 0.03% in NTG has been reported 
to be in the range of 12.7% to 20% and 16% to 21.6%, 
respectively.10,13,20,21 Travoprost 0.004% has been reported to 
have similar results (16.7% to 25.1%).17,18 Our results are in 
accordance with the results of these previous studies.
Ang et al18 published the only report showing the effect of 
travoprost on daytime IOP in NTG. These authors reported 
a mean IOP reduction of 16.1%, a maximum IOP reduction 
of 13.5%, a 43% rate of .20% IOP reduction, and a 30% 
rate of ,10% IOP reduction (considered as TNR) in both 
mean and maximum IOP. These findings are considerably 
worse than our results. We suspect that this disparity may be 
due to measurement of daytime IOP only and that maximum 
and minimum IOP may have changed outside of daytime 
hours in the earlier study.7,8 Another possible explanation Clinical Ophthalmology: 2010:4 submit your manuscript | www.dovepress.com
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is that the earlier investigators included both eyes in their 
study, which may have led to a TNR double-counting 
error. Additionally, 96% of their patients were Caucasians. 
Netland et al22 reported that travoprost is more effective in 
blacks than nonblacks, so patient race might influence this 
result.   Furthermore, Suh et al17 reported the effect of travo-
prost 0.004% during 12 months of treatment and noted that 
IOP reduction was evident at one month; however, a slight 
increase in IOP occurred between nine and 12 months. 
Almost all of our data were obtained within a one- to two-
month period after the beginning of travoprost treatment, 
whereas the data from the study by Ang et al were obtained 
at six months.18
Achievement of an IOP reduction greater than 30% as 
recommended by the CNTG study group is very difficult using 
a single, topical antiglaucoma eye drop.10–13,17,18,20,21 In our 
study, the rates of 30% IOP reduction are 23.5% for maximum 
24-hour IOP and 11.8% for mean 24-hour IOP. When a topical 
combination therapy is needed to achieve the target reduction 
in IOP, travoprost without BAK is a superior option because 
preservatives such as BAK can induce conjunctival inflamma-
tion and affect success rates for filtering surgery.23,24
However, reduction of IOP alone is considered to be 
insufficient for the management of NTG. Hemodynamic 
factors such as ocular perfusion pressure (OPP) are also 
reported to be important.25–27 Among the topical antiglaucoma 
eye drops, the prostaglandin F2-alpha analogs (travoprost, 
latanoprost, and bimatoprost) and dorzolamide increase 
OPP, whereas timolol, a beta-blocker, and brimonidine do 
not.28–30 Therefore, to investigate the effect of eye drops, 
both the reduction in IOP and the hemodynamic effects of 
the medication should be evaluated.
The present study suggests that travoprost reduces IOP 
throughout a 24-hour period in NTG patients, and an IOP 
reduction greater than 20% was observed in over half of 
the eyes examined. However, our study reported short-
term results in a small group of patients in whom IOP was 
measured during only one 24-hour period, and we com-
pared these results retrospectively with untreated 24-hour 
IOP measurements made one to two months earlier, prior 
to the started of travoprost. Further long-term, large-scale, 
prospective studies are needed to compare our findings 
with the effects of other prostaglandin analogs on 24-hour 
IOP in NTG.
Table 2 Changes in iOP and percentage change from baseline in the treated eye
Travoprost Baseline IOP reduction (%) P value
Clinic iOP 11.2 ± 2.4 14.8 ± 2.7 24.3% ,0.001
Mean 24-hour iOP 10.3 ± 2.0 12.9 ± 2.2 20.2% ,0.001
Maximum 24-hour iOP 12.4 ± 2.5 15.4 ± 2.7 19.5% ,0.001
Minimum 24-hour iOP 8.5 ± 1.9 10.5 ± 2.2 19.0% ,0.001
24-hour IOP fluctuation 3.9 ± 1.5 4.9 ± 1.2 20.4% ,0.05
Values indicate mean mmhg ± sD.
Abbreviations: iOP, intraocular pressure; sD, standard deviation.
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Figure 2 IOP measurements from the fellow eye over 24 hours. There is no significant IOP reduction at each time point (P . 0.05).
Abbreviation: iOP, intraocular pressure.Clinical Ophthalmology
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